The FDA has granted full approval for Sprycel (dasatinib tablets, from Bristol-Myers Squibb), an oral tyrosine kinase inhibitor, for the treatment of adults in all phases of chronic myeloid ...

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL ® (dasatinib) Support, a useful ...

Bristol-Myers Squibb CompanyBMY announced that the European Commission (EC) has approved its oncology drug Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric ...